NCT06035731

Brief Summary

the 3-year randomized controlled RCT-SE study aims to investigate Socio-aesthetics well being care on quality of life, pain and anxiety. The primary objective is to show that socio-aesthetics well being care improves quality of life during cancer treatment, compared to self care administration of dermo-cosmetics products The secondary objectives are to show that socio-aesthetics well being care significantly reduced anxiety and pain compared to self care administration of dermo-cosmetics products

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
11mo left

Started May 2024

Typical duration for not_applicable

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress69%
May 2024Apr 2027

First Submitted

Initial submission to the registry

August 29, 2023

Completed
15 days until next milestone

First Posted

Study publicly available on registry

September 13, 2023

Completed
8 months until next milestone

Study Start

First participant enrolled

May 15, 2024

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2026

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2027

Last Updated

September 8, 2025

Status Verified

August 1, 2025

Enrollment Period

2.5 years

First QC Date

August 29, 2023

Last Update Submit

September 1, 2025

Conditions

Keywords

SOCIO-AESTHETIC

Outcome Measures

Primary Outcomes (1)

  • Patient Centricity Questionnaire (PCQ): Patient reported outcome: impact of supportive care

    Patient Centricity Questionnaire (PCQ): (0-110) higher scores mean better outcome

    up to 12 weeks

Secondary Outcomes (2)

  • pain EVA

    up to 12 weeks

  • Anxiety

    up to 12 weeks

Study Arms (2)

group A: well-being care performed by SOCIO-AESTHETICS

EXPERIMENTAL

Group A will benefit from 4 sessions of well being care performed by a qualified socio-aesthetics, during 4 consecutive chemotherapy administrations. Patients included will have following interventions : quality of life: PCQ Pain: EVA Anxiety: HADS

Other: SOCIO-AESTHETICS care

group B: control

NO INTERVENTION

Group B (control) will apply the dermo-cosmetic products themselves (self-care) without intervention of the socio-aesthetician, during 4 consecutive chemotherapy administrations. quality of life: PCQ Pain: EVA Anxiety: HADS

Interventions

SOCIO-AESTHETICS well being care performed by qualify person

group A: well-being care performed by SOCIO-AESTHETICS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • over 18 years old
  • treated with chemotherapy for lung , breast, colon or prostate cancer
  • Able to understand, read, and write French,
  • Affiliated with a social security scheme,
  • Having dated and signed an informed consent.

You may not qualify if:

  • Unable to be followed for medical, social, family, geographic or psychological reasons for the duration of the study,
  • Deprived of their liberty by court or administrative decision,

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Centre Antoine Lacassagne

Nice, France

RECRUITING

AP HP

Paris, France

RECRUITING

Chru Tours

Tours, France

RECRUITING

MeSH Terms

Conditions

Colonic NeoplasmsLung NeoplasmsBreast NeoplasmsProstatic NeoplasmsCancer Pain

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesGenital Neoplasms, MaleUrogenital NeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Guillaume Guillaume

    CH VALENCE

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Guillaume Guillaume, PHD

CONTACT

sandrine Beauchard

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: open label, randomized, controlled, multicenter intervention study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 29, 2023

First Posted

September 13, 2023

Study Start

May 15, 2024

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

April 1, 2027

Last Updated

September 8, 2025

Record last verified: 2025-08

Locations